| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |
Interdisciplinary Oncology Program, H. Lee Moffitt Cancer Center and Research Institute [C. A. M-C., T. M-A.] and Department of Pathology [C. A. M-C., S. L.], University of South Florida, Tampa, Florida 33612, and Department of Pharmacology and The Puerto Rico Cancer Center, University of Puerto Rico, Rio Piedras, Puerto Rico 00936 [K. R-O.]
 |
ABSTRACT |
|---|
 Top ABSTRACT INTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
Experimental Design: Thirteen archived head and neck squamous cell carcinomas were selected from the files of the Pathology Department of the H. Lee Moffitt Cancer Center. Protein immunoexpression was quantitated by image analysis in the context of histopathological parameters. Mutation analysis of the MADR2/Smad2 gene was also performed.
Results: In both TßR-II-positive and TßR-II-negative tumors, expression of the non-TGF-ß-specific Smads (4, 6, and 7) was variable, whereas expression of the pathway-specific Smad2 was lost in 38% of the tumors. Expression of the activated, phosphorylated form of this molecule, Smad2-P, was lost in approximately 70% of the tumors. No abnormal mRNA expression and no mutations in the MADR2/Smad2 gene were observed.
Conclusions: These results suggest that multiple defects in TGF-ß signaling, both at the receptor and postreceptor level, may play a role in the oncogenesis of head and neck squamous cell carcinoma.
|
INTRODUCTION |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
The demonstration that TGF-ß has antiproliferative effects in a variety of cell types has led to the hypothesis that inactivation of the TGF-ß-signaling pathway contributes to tumor development or progression (9) . Thus, the TGF-ß-signaling pathway has been postulated to be a tumor suppressor pathway, which is operational in normal cells and functions by delaying progression through the cell cycle. Consistent with this hypothesis, alterations have been identified in many components of this pathway. Mutations in Smad4 (DPC4) and Smad2 (MADR2) have been reported in pancreatic, colon, and lung cancer (10, 11, 12, 13, 14) . Both of these Smads have been mapped to 18q21, a region often deleted in several human cancer types.
It has been reported previously (15 , 16) that, in pancreatic cancer, Smad6 and Smad7 are overexpressed, suggesting that this is a mechanism of repression of the TGF-ß-signaling pathway. In an analysis of human epithelial skin tumors, however, no differences were found in Smad2, Smad6, and Smad7 expression (17) . None of these studies examined the expression of activated Smad2 (the Smad2 phosphorylated, Smad2-P). In this study, we have observed variable expression of the Smads that are not pathway-restricted. However, expression of the TGF-ß/activin pathway-restricted Smad2 was greatly diminished in poorly differentiated HNSCC. This decrease in the expression of Smad2 was independent of the expression of other components of the TGF-ß pathway.
|
MATERIALS AND METHODS |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
The diagnosis of squamous cell carcinoma was made by a head and neck pathologist using standard criteria that included the presence of intracellular bridges, keratinization, keratin pearl formation, various degrees of cytological atypia, mitotic rate, and architectural abnormalities. The degree of differentiation was assigned as follows: (a) well differentiated, large cells with obvious keratinization, intercellular bridges, or keratin pearl formation; (b) moderately differentiated, heterogeneous population of cells of moderate size with only focal keratinization, poorly preserved intercellular bridges, and higher degree of cytological atypia; and (c) poorly differentiated, anaplastic population lacking keratinization and intercellular bridges and with minimal resemblance to squamous epithelium. Definitive stromal infiltration required desmoplastic reaction associated with ragged tumor borders. The superficial component of the invasive carcinoma was defined as that region of the tumor in continuity with the overlying squamous epithelium that invaded the underlying stroma up to a distance of approximately 300 µm. Within this distance, there is a high probability of angiolymphatic invasion. Deep invasion was defined as those areas of the tumor invading to a distance more than 300 µm and/or with tumor tongues separated from the main mass. Clinicopathological staging was assigned following the recommendations of the American Joint Committee on Cancer (18) .
Immunohistochemical Analysis of TGF-ß Receptors and Smads.
Five-µm sections from formalin-fixed, paraffin-embedded tissues were cut and placed on poly-L-lysine-coated slides. Slides were subjected to deparaffination in xylene and hydration through a series of decreasing alcohol concentrations, following standard procedures. Endogenous peroxidase was quenched with a 3% solution of H2O2 for 20 min at 37°C. Slides were then washed in deionized water for 5 min. Antigen retrieval was performed by placing the slides in a clear plastic container with a vented top containing citrate buffer [10 mM citric acid, 10 mM sodium citrate (pH 6.0)] in a microwave oven set on high 2 times for 5 min each. The slides were then allowed to cool for 10–20 min, rinsed in deionized water, placed in PBS for 5 min, and drained. Blocking serum was applied, and the slides were incubated in a humid chamber for 20 min at room temperature. After blotting, the following primary antibodies were applied at room temperature at a 1:100 dilution: anti-TßR-II (COOH-terminal domain; Ref. 19
); anti-Smad2 (Upstate Biotechnology, Lake Placid, NY); anti-Smad2-P (Upstate Biotechnology); anti-Smad3 (Zymed Laboratories, San Francisco, CA); anti-Smad4 (Upstate Biotechnology); anti-Smad6 (Zymed Laboratories), anti-Smad7 (Santa Cruz Biotechnology); and Ki-67 (Dako Corporation, Carpinteria, CA). After 1 h, the slides were rinsed with PBS and placed in PBS for 5 min. For detection, the Vectastain ABC Kit, Rabbit IgG, Elite series (Vector Laboratories, Inc., Burlingame, CA) was used following the manufacturer’s specifications. The biotinylated secondary antibody was applied for 20 min at room temperature in a humid chamber. At the end of this incubation, the slides were rinsed and placed in PBS for 5 min, followed by the addition of the avidin-biotin complex. The slides were incubated in a humid chamber for 30 min at room temperature and then rinsed and placed in PBS for 5 min. 3,3'-diaminobenzidine, prepared following the manufacturer’s specifications, was applied to the slides, and color development was monitored for 5 min. Slides were rinsed in water, counter-stained with modified Mayer’s hematoxylin for 30 s, washed in running water for 10 min, dehydrated, cleared, and mounted with resinous mounting medium.
Image Analysis.
The Optimas 6.5 software (Media Cybernetics, Inc., Seattle, WA) was used to quantitate protein expression. The ROIs (normal squamous epithelium, dysplasia, carcinoma in situ, and superficial and deep components of the tumor) were stored as TIFF images using identical magnifications (x40) and camera settings. The total number of nuclei in a given ROI was determined, and constant thresholds were set to discriminate between the brown color of positive nuclei and the negative (blue) nuclei. A protein index was determined as the percentage of positive versus total nuclei.
Statistical Analysis.
Protein quantitation, expressed as an index, was compared between the different groups using the Wilcoxon rank-sum (Mann-Whitney U) test.
PCR and Reverse Transcription-PCR Analysis.
Genomic DNA and total RNA were obtained from fresh-frozen tissues stored at the H. Lee Moffitt Cancer Center Tissue Procurement Laboratory. cDNA was synthesized from 10 µg of total cellular RNA by reverse transcription with Moloney murine leukemia virus reverse transcriptase (Life Technologies, Inc.) using random hexamers as primers. The 
-actin sense (5'-CCCGGTGCTTCTGACCGAGGCC-3') and antisense (5'-CAGACTGAGTACTTGCGCTC-3') primers were used as positive controls for the genomic DNA and the reverse transcription reaction. These primer combinations allowed us to distinguish by size the origin (DNA or spliced mRNA) of the PCR products (20)
. The sequences of the DPC4 and Smad2 sense and antisense primers have been described before (11)
. The PCR mixture contained 50 mM Tris (pH 9.0), 50 mM KCl, 1.5 mM MgCl2, 0.01% gelatin, 100 ng of each primer, and 1 unit Taq polymerase (Life Technologies, Inc.). After an initial denaturation at 94°C for 5 min, amplification was carried out for 30 cycles at 94°C for 30 s, 55°C for 1 min, and 72°C for 1 min, followed by a final elongation step at 94°C for 2 min, 55°C for 2 min, and 72°C for 10 min. The PCR products were resolved on a 2% agarose gel and stained with ethidium bromide.
|
RESULTS |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
, the distribution pattern of protein expression across epithelial layers suggests a favored location for the various TGF-ß-signaling molecules. This pattern seems to correlate with the accepted interpretation of the role that Smad molecules play in cellular proliferation, as revealed by Ki-67 immunostaining. Thus, proliferating basal and parabasal layers tend to express with higher intensity the inhibitory Smads (specifically Smad7), whereas upper, more quiescent, and mature layers tend to predominantly express the TGF-ß pathway-specific Smad2. The TGF-ß pathway-specific Smad3 and the common pathway Smad4 are expressed in all of the layers, and the TßR-I and TßR-II are distributed across layers with a variable pattern (data not shown). Thirteen squamous cell carcinomas were included in this study (see Table 1
). The age of the patients ranged from 54 to 82 years with an average of 66. Twelve patients (92%) were male and one (8%) was female. The anatomical location of the tumors included lip, tongue, floor of the mouth, larynx, and the tonsillar region. As can be seen in Table 1
, the common Smads (Smad4, Smad6, and Smad7) showed variable expression. The TGF-ß pathway-specific Smad3 was consistently expressed in a nuclear location in both the tumor and the non-neoplastic adjacent epithelium. Expression of the other TGF-ß pathway-specific Smad, Smad2, was more difficult to ascertain because differences in expression and intensity were observed with different antibodies. The cases listed in Table 1
were evaluated using three different antibodies on consecutive sections of the same tissue block as described in "Materials and Methods." For two of the antibodies (see "Materials and Methods"), no competing peptide was available; however, for one of the antibodies, competing peptide was used to ascertain binding specificity. The data presented in Table 1
describe Smad2 expression consistently obtained with two of these antibodies. As can be seen, Smad2 is lost in 38% of cases. It is preserved in 75% of the well-differentiated tumors and 50% of the poorly differentiated tumors. However, all of the poorly differentiated tumors lacked expression of the activated pathway-specific Smad2-P. Both molecules, Smad2 and Smad2-P, were expressed simultaneously in only three tumors (23%). Fig. 2
depicts the expression of TGF-ß-signaling molecules in a representative TßR-II-positive, well-differentiated tumor. As can be seen, the non-neoplastic squamous epithelium expresses Smad2 (Fig. 2A)
, nuclear Smad2-P (Fig. 2B)
, Smad3 (Fig. 2C)
, Smad4 (Fig. 2D)
, Smad6 (Fig. 2E)
, and Smad7 (Fig. 2F)
. In the adjacent tumor, however, the expression of Smad2-P is lost (Fig. 2H)
. In this particular tumor, other Smads (Smad4, Smad6, and Smad7) are expressed (Fig. 2, J–L)
, and both TßR-I and TßR-II expression was maintained (data not shown). Fig. 3
shows the quantitation steps followed to measure Smad2-P in a representative case. Smad2-P-positive nuclei (brown) and -negative nuclei (blue) are counted by the software to determine the protein index. Image analysis quantitation shows (Table 2)
that the non-neoplastic epithelium adjacent to the tumor has a Smad2-P index significantly higher (44.3 ± 14.7) than either moderately differentiated (16.19 ± 3.0) or poorly differentiated (6.52 ± 5.7) tumors. This is independent of levels of TßR-II expression (data not shown).
|
|
|
|
|
. Smad2 cDNA PCR amplification was done using overlapping primer combinations that have been used previously (11)
for mutational analysis by single-strand conformational polymorphism. Single-strand conformational polymorphism analysis using the conditions described before did not detect any mutations in the tumors examined (data not shown). It could be argued that in some tumors a deletion of the gene could be masked by contamination with normal tissue. However, our data are in agreement with what has been reported in other studies of head and neck tumors (22)
, where mutations of the TßR-II, MADR2/Smad2, and DPC4/Smad4 genes are found only rarely, suggesting that, in these tumors, lack of Smad2 protein expression is attributable to mechanisms other than genetic alterations.
|
|
DISCUSSION |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
In analogy to colon cancer, several groups have proposed that tumorigenesis in HNSCCs is a multistep process driven by the accumulation of genotypic and phenotypic alterations (26, 27, 28) . Several groups have examined the expression of oncogenes and tumor suppressor gene products in squamous cell carcinomas. Accumulation of the p53 protein (suggesting possible mutations) and cyclin D1 overexpression have been documented (29 , 30) . However, no significant association between immunohistochemical detection of p53 protein and survival has been found in patients with advanced head and neck cancer (31, 32, 33) . Therefore, it has been concluded that although p53 protein accumulation occurs early in the pathogenesis of oral cavity cancers, it does not appear to have prognostic significance (33) . Recently, 100 archived squamous cell carcinomas of the oral cavity were examined to identify tumor-associated alterations in normal adjacent mucosa (34) . No correlation was found in expression of p53, Mdm2, Bcl-2, and p21WAF1/CIP1 between tumors and adjacent mucosa.
TGF-ß signaling requires the formation of hetero-oligomeric receptor complexes, most likely a heterotetramer, containing two molecules each of TßR-I and TßR-II (35, 36, 37) . A model for the mechanism of action of this heterotetramer complex has been proposed by Wrana et al. (36) . In this model, TßR-II is constitutively autophosphorylated. Ligand binding causes recruitment and phosphorylation of TßR-I, the kinase activity of which is essential for the phosphorylation of downstream substrates and biological responses. After complex formation and phosphorylation of TßR-I, a phosphorylation cascade of downstream cytoplasmic substrates, including the Smad proteins, is activated (1 , 38) . Downstream events in the TGF-ß-signaling pathway include complex formation of Smad2 or Smad3 with Smad4, translocation of the Smad/Smad4 complex to the nucleus, and eventual activation of target genes (1) . In the absence of ligand, the inhibitory Smads, Smad6 and Smad7, are localized predominantly in the nucleus. Upon TGF-ß receptor activation, they accumulate in the cytoplasm (39) and associate with the ligand-activated TGF-ß receptor complex in the cell membrane, antagonizing TGF-ß family signaling by preventing the activation of signal-transducing Smad complexes.
Studies (9) on the TGF-ß antiproliferative effects in a variety of cell types strongly suggest that inactivation of the TGF-ß-signaling pathway contributes to tumor development or progression. Thus, we hypothesized that a defect in any of the components of the TGF-ß-signaling pathway might render the pathway inactive, contributing to the malignant phenotype of HNSCC. A decrease in the number of TßR-II-binding sites has been associated with loss of responsiveness to TGF-ß (40, 41, 42, 43, 44, 45, 46, 47, 48, 49) . This decrease in TßR-II expression correlates with tumorigenicity in many cell lines (48 , 50) . We have reported previously (21) that TßR-II expression decreases as HNSCCs become less differentiated and more biologically aggressive. In a small subset of tumors, however, TßR-II expression was maintained.
Analysis of the expression of TGF-ß intracellular signaling molecules (Smads) in HNSCC reveals that expression of the activated pathway-specific Smad2-P is lost in a significant percentage of these tumors. Lack of expression of Smad2 and/or Smad2-P could further contribute to signaling abnormalities at a postreceptor level in tumors with abnormal receptor expression and be responsible for defective signaling in tumors with normal receptor expression (TßR-II; Ref. 21 ). Interestingly, the expression of the TGF-ß pathway-specific Smad3 was not lost in any of the tumors examined. It is possible, however, that examination of an activated form of Smad3 would reveal changes in patterns of expression. In our study, four TßR-II-positive tumors express Smad2-P, suggesting that the inability to respond to TGF-ß antiproliferative response might be attributable to other defects, perhaps in genes that are downstream targets of the Smads.
Expression of the Smads that are not TGF-ß-specific (4 , 6 , and 7) in tumors was similar to that of adjacent non-neoplastic squamous epithelium. This is not surprising, because many different pathways use these molecules, and their absence may be incompatible with cell survival. This has also been reported (17) in skin tumors where no significant differences were observed in the expression of Smad4, Smad6, and Smad7 between tumor and nontumoral cells. This is in contrast to reports (15 , 16) in pancreatic cancer, however, where overexpression of the inhibitory Smads, Smad6 and Smad7, has been proposed as another mechanism for inactivation of the TGF-ß-signaling pathway. Our data supports the hypothesis that aberrant expression of critical molecules may play a role in the inactivation of the TGF-ß pathway at different levels contributing to HNSCC tumorigenesis.
Loss of heterozygosity in chromosome 18q has been reported frequently in HNSCCs (51, 52, 53) . Both the DPC4/Smad4 and MADR2/Smad2 genes have been mapped to 18q (10 , 11) , and genetic alterations in the DPC4/Smad4 and MADR2/Smad2 genes have been reported in human colon and pancreatic cancers, in which 18q is frequently lost (54) . In head and neck cancers, however, our amplification of both DPC4/Smad4 and MADR2/Smad2 genes has failed to reveal loss of this chromosomal region. This is in agreement with what has been recently reported by Takebayashi et al. (55) who analyzed the minimally lost areas of 18q in 57 HNSCCs. In this analysis, both the MADR2/Smad2 and the DPC4/Smad4 genes were always present, suggesting that other tumor-suppressor gene(s) may be involved in tumors with observed loss of heterozygosity in 18q.
Mutations of DPC4/Smad4, Smad3, and MADR2/Smad2 genes have been reported in pancreatic (10) , colon (11 , 12) , lung (13 , 14) , and ovarian cancers (56) . Analysis of other Smad genes (i.e., Smad 1, 5, and 6) in a variety of tumors, including those from colon, breast, lung, and pancreas, revealed no mutations (22 , 54) . The genetic changes found in Smad3 in over 40% of ovarian cancers are not accompanied by amino acid changes, probably representing a polymorphism not involved in tumorigenesis (56) . We found that the lack of expression of Smad2 protein in head and neck tumors is not attributable to genetic alterations, as reported for colon and pancreatic cancers. This is in agreement with what has been reported in head and neck, hepatocellular, breast, lung, ovary, and prostate carcinomas (14 , 22 , 45 , 56, 57, 58, 59, 60, 61, 62, 63) , where mutations of the TßR-II, MADR2/Smad2, and DPC4/Smad4 genes are rare. This suggests that genetic instability in other Smad genes does not account for the widespread resistance to TGF-ß.
|
FOOTNOTES |
|---|
1 Supported in part by the American Cancer Society Grant #RPG-98-039-01-CNE. 
2 To whom requests for reprints should be addressed, at H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33612. Phone: (813) 979-3884; Fax: (813) 979-3893; E-mail: antoniaT{at}moffitt.usf.edu
3 The abbreviations used are: TGF, transforming growth factor; TßR-I, TGF-ß type I receptor; HNSCC, head and neck squamous cell carcinoma; ROI, region of interest; SCCHN, squamous cell carcinoma of the head and neck.
Received 11/27/00; revised 2/17/01; accepted 3/ 1/01.
|
REFERENCES |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
This article has been cited by other articles:
|
|
 |
|
  W. M. Grady Transforming Growth Factor-{beta}, Smads, and Cancer Clin. Cancer Res., May 1, 2005; 11(9): 3151 - 3154. [Full Text] [PDF]
|
|
|
|
|
|
A. Baez, A. Cantor, S. Fonseca, M. Marcos-Martinez, L. A. Mathews, C. A. Muro-Cacho, and T. Munoz-Antonia Differences in Smad4 Expression in Human Papillomavirus Type 16-Positive and Human Papillomavirus Type 16-Negative Head and Neck Squamous Cell Carcinoma Clin. Cancer Res., May 1, 2005; 11(9): 3191 - 3197. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.S. Prime, M. Davies, M. Pring, and I.C. Paterson THE ROLE OF TGF-{beta} IN EPITHELIAL MALIGNANCY AND ITS RELEVANCE TO THE PATHOGENESIS OF ORAL CANCER (PART II) Critical Reviews in Oral Biology & Medicine, November 1, 2004; 15(6): 337 - 347. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. T. Maliekal, R. J. Anto, and D. Karunagaran Differential Activation of Smads in HeLa and SiHa Cells That Differ in Their Response to Transforming Growth Factor-{beta} J. Biol. Chem., August 27, 2004; 279(35): 36287 - 36292. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. H. Tannehill-Gregg, D. F. Kusewitt, T. J. Rosol, and M. Weinstein The Roles of Smad2 and Smad3 in the Development of Chemically Induced Skin Tumors in Mice Vet. Pathol., May 1, 2004; 41(3): 278 - 282. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Tian, S. DaCosta Byfield, W. T. Parks, S. Yoo, A. Felici, B. Tang, E. Piek, L. M. Wakefield, and A. B. Roberts Reduction in Smad2/3 Signaling Enhances Tumorigenesis but Suppresses Metastasis of Breast Cancer Cell Lines Cancer Res., December 1, 2003; 63(23): 8284 - 8292. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Beuschlein, B. D. Looyenga, S. E. Bleasdale, C. Mutch, D. L. Bavers, A. F. Parlow, J. H. Nilson, and G. D. Hammer Activin Induces x-Zone Apoptosis That Inhibits Luteinizing Hormone-Dependent Adrenocortical Tumor Formation in Inhibin-Deficient Mice Mol. Cell. Biol., June 1, 2003; 23(11): 3951 - 3964. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. L. Ferris and W. M. Koch Connective Tissue Disease Coincident With Nasopharyngeal Carcinoma: Two Sporadic Cases in a Western Population Arch Otolaryngol Head Neck Surg, January 1, 2003; 129(1): 101 - 105. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Fukuchi, Y. Fukai, N. Masuda, T. Miyazaki, M. Nakajima, M. Sohda, R. Manda, K. Tsukada, H. Kato, and H. Kuwano High-Level Expression of the Smad Ubiquitin Ligase Smurf2 Correlates with Poor Prognosis in Patients with Esophageal Squamous Cell Carcinoma Cancer Res., December 15, 2002; 62(24): 7162 - 7165. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. B. Glaser, J. Li, M. E. Aakre, D. W. Morgan, G. Sheppard, K. D. Stewart, J. Pollock, P. Lee, C. Z. O'Connor, S. N. Anderson, et al. Transforming Growth Factor {beta} Mimetics: Discovery of 7-[4-(4-Cyanophenyl)phenoxy]-Heptanohydroxamic Acid, a Biaryl Hydroxamate Inhibitor of Histone Deacetylase Mol. Cancer Ther., August 1, 2002; 1(10): 759 - 768. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Adnane, C. Muro-Cacho, L. Mathews, S. M. Sebti, and T. Munoz-Antonia Suppression of Rho B Expression in Invasive Carcinoma from Head and Neck Cancer Patients Clin. Cancer Res., July 1, 2002; 8(7): 2225 - 2232. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
